Ro/SSA and La/SSB specific IgA autoantibodies in serum of patients with Sjögren’s syndrome and systemic lupus erythematosus

Nader Pourmand, Marie Wahren-Herlenius, Iva Gunnarsson, Elisabet Svenungsson, Björn Löfström, Yiannakis Ioannou, David A Isenberg, Carl G M Magnusson

Abstract

Objective—To investigate the occurrence of IgA autoantibodies to Ro 52 kDa, Ro 60 kDa and La antigen in serum of patients with primary Sjögren’s syndrome (pSS) and systemic lupus erythematosus (SLE).

Methods—Recombinant Ro 52 kDa, Ro 60 kDa and La antigens were used to analyse autoantibodies in serum from 25 patients with pSS, 30 patients with SLE and 20 controls using a semiquantitative immunoblotting approach.

Results—Among the patients with pSS, 21 (84%) had detectable IgA autoantibodies to Ro 52 kDa, 13 (52%) to Ro 60 kDa and 20 (80%) to La antigen. The corresponding results for the patients with SLE were 22 (73%), 14 (47%) and 20 (67%), respectively. No IgA autoantibodies against the three antigens were detected in 20 normal controls. A comparison of several clinical features with the titres of IgA antibodies to Ro 52 kDa, Ro 60 kDa and La, revealed a significant relation between IgA anti-Ro 52 and IgA anti-La to sicca (p<0.05). Semiquantitative data suggest that IgG is the dominating antibody to the three antigens followed by IgM > IgA in both SLE and pSS patients. Specificity studies of IgA autoantibodies with different subfragments of Ro 52 kDa and Ro 60 kDa antigens showed that IgA antibodies did not differ from IgG and IgM in their recognition pattern.

Conclusion—These results suggest that besides IgM and IgG, IgA autoantibodies are also detected at high frequency in patients with pSS and SLE. Further studies are necessary to evaluate the contribution of these IgA autoantibodies to inflammation as well as their diagnostic value.


The clinical relevance of measuring IgG and IgM autoantibodies to Ro/SSA and La/SSB has been established over the past 30 years. The Ro/SS-A autoantigen is a small intracellular RNA-protein complex. It consists of a 60 kDa protein associated with one of four RNAs of 83–112 bases, termed hY RNAs.1 2 This complex is at least transiently associated with the La polypeptide,3 which has been reported to take part in the maturation process of RNA polymerase III transcripts by binding to the uridine-rich 3’ends.4 5 The association of a 52 kDa protein with the Ro/SS-A antigen was described later6 and it is thought to associate with the complex via the 60 kDa protein.6 No sequence homology exists between the 52 kDa and 60 kDa proteins.10-11 Whether the Ro 52 kDa protein is permanently associated with the Ro ribonucleoprotein or not,6 14 15 and to which cellular compartment the Ro 52 kDa protein is located,6 16-18 are still unresolved questions.

IgG and IgM autoantibodies to these antigens have been detected in patients with primary or secondary Sjögren’s syndrome (SS), systemic lupus erythematosus (SLE) and related disorders, and are now regarded as one of the hallmarks of these diseases. These antibodies are associated in particular with photosensitive rashes, subacute cutaneous lupus, neonatal lupus and congenital heart block, but their contribution to the pathogenesis of these diseases remains unclear19 20.

In contrast with the vast literature on IgG and IgM autoantibodies there are, to our knowledge, only a few studies on Ro/SSA and La/SSB-specific IgA autoantibodies.21-23 Previously, total serum IgA concentrations have been reported to be high in patients with SS and SLE but no correlation with clinical features has been established.24-26

The aim of this report was to study IgA autoantibodies to Ro 52 kDa, Ro 60 kDa and La in serum of patients with pSS and SLE. A semiquantitative immunoblotting approach permitted comparison of the IgA results to clinical features, as well as to the specificity and levels of IgG and IgM.

Methods

PATIENT AND CONTROL SERA

Sera from 25 patients (24 F/1 M; median age 64; range 29–86 years) who met the European criteria for primary Sjögren’s syndrome (pSS)27 were supplied by the Centre for Rheumatology/Bloomsbury Rheumatology Unit, Department of Medicine, University College London, England. Thirty sera from patients with SLE who had four or more of the revised criteria of the American College of Rheumatology (ACR),28 (27 F/3 M; median age 52; range 22–82 years) were obtained from the Department of Medicine, Rheumatology Unit, Karolinska Hospital, Stockholm, Sweden. All 55 patient sera were Ro/SSA and La/SSB positive by immunodiffusion or counter immunoelectrophoresis. Clinical and serological features typical of SLE and pSS were recorded. These included dermal manifestations, serositis, nephritis, arthritis,
CNS symptoms, haematological manifestations, sicca symptoms (defined as severe and continuous problems with dryness in mouth and eyes. In most cases, the diagnosis was also confirmed by measurements of salivation and Schirmer's test), and rheumatoid factor (RF). In the SLE patients, secondary Sjögren's syndrome was determined by noting the relevant clinical history and demonstrating objective dryness of both eyes and mouth. All sera were stored at −70°C until use. As controls, sera from 20 randomly selected healthy blood donors were used.

**EXPRESSION AND PREPARATION OF RECOMBINANT PROTEINS**

cDNA clones of Ro 52 kDa, Ro 60 kDa, and La 48 kDa and a set of subclones were expressed with maltose binding protein (MaBP) as fusion partner in *Escherichia coli* TB1 strain in the pMAL vector system (New England Biolabs, Beverly, MA, USA) as described previously.29–31 Figure 1 illustrates the constructs used in this paper.

Expression of recombinant proteins was induced by 0.3 mM isopropyl-β-D-thiogalactoside at 37°C for two hours. Bacteria from induced cultures were spun down and pellets frozen at −70°C overnight. After thawing for 30 minutes, addition of Triton X-100 to 0.1% and incubation for another 10 minutes, the pellets were sonicated six times for 10 seconds with a Branson sonifier (Optilab, Stockholm, Sweden) at setting 4. After centrifugation for 15 minutes at 12 000 g, supernatants were used as the source of soluble antigens following purification on an amylose column according to the manufacturer's instructions (New England Biolabs). Protein concentrations were determined with the Bio-Rad Protein-assay (Bio-Rad Sundbyberg, Sweden) using BSA as standard. Insoluble full length Ro 60 kDa fusion protein, pelleted after the sonication step was first extracted with 1 M urea and thereafter with 6 M urea. The 6 M urea preparation was used as antigen source in immunoblotting.

**ABSORPTION PROCEDURE**

An excess of protein G Sepharose 4 Fast Flow (Pharmacia Biotech, Uppsala, Sweden) was used to deplete IgG from the serum samples for subsequent IgA and IgM antibody detection. Protein G is known to react with all four human IgG subclasses but neither with human IgA nor human IgM.32 Three volumes of protein G Sepharose (50% suspension) and one volume of serum were mixed, and PBS-TW (phosphate buffered saline containing 0.05% Tween 20, pH 7.4) added to the

Figure 1  **Schematic representation of Ro 60 kDa, Ro 52 kDa and La proteins.** The hatched boxes indicate the position of RNA binding domains, the dark grey boxes indicate the position of Cys/His clusters and the grey box represents the hydrophilic putative alpha-helical region with an incomplete and a complete leucin zipper indicated by open boxes. Amino acid positions are indicated by numbers. The number of amino acid residues encoded by each clone is indicated inside the corresponding open bar. The position of the clones relative to the deduced Ro 52 kDa, Ro 60 kDa and La amino acid sequence is indicated to the right. (A) Ro 60 kDa protein and three subclones. (B) Ro 52 kDa protein and three subclones. (C) La protein.
Figure 2. Illustration of the use of chimeric IgA anti-NIP antibodies to semiquantitatively immunoblotting data. BSA-NIP conjugate was separated on SDS-PAGE and transferred to a blotting membrane. After incubation with different concentrations of IgA anti-NIP antibodies (0–64 ng/ml) the membrane was incubated with anti-IgA enzyme conjugate and developed with BCP/NBT for 30 minutes.

Ro/SSA and La/SSB specific IgA

Ro–52 52–4 52–5 52–6
Ro–60 60–E 60–G 60–K

Results

with PBS-TW and incubated for 15 minutes at room temperature with PBS-TW containing 2% bovine serum albumin (BSA) and 4% milk powder to block non-specific binding sites. Membranes were washed three times with PBS-TW and cut into 1.0–1.5 mm wide strips and incubated in eight well trays with diluted patient serum or with sera that had been pre-incubated with protein G Sepharose for two hours. The strips were washed four times with PBS-TW before addition of rabbit antihuman anti-IgA (1:500) or antihuman anti-IgM (1:1200) antibodies in the form of alkaline phosphatase-conjugated F(ab')2-fragments. After incubation for three hours at room temperature, and four washes, the strips were developed for 30 minutes with Nitro Blue Tetrazolium/5-Bromo-4-Chloro-3-Indolyl Phosphate, (Sigma, St Louis, MO, USA). IgG antibodies were similarly detected with alkaline phosphatase conjugated rabbit antihuman IgG antibodies (Dakopatts AB, Stockholm, Sweden) at a 1:2000 dilution. All samples, standards and conjugates were diluted in PBS-TW containing 0.2% BSA and 0.4% milk powder.

Table 1. Frequency of detectable antigen-specific IgG, IgM and IgA autoantibodies in patients with SLE (n=30), pSS (n=25) and normal controls (n=20) by immunoblotting

<table>
<thead>
<tr>
<th>Antigen</th>
<th>Ig Class</th>
<th>Control (%)</th>
<th>SLE n (%)</th>
<th>pSS n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ro 52</td>
<td>IgG</td>
<td>24 (80)</td>
<td>21 (84)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>IgM</td>
<td>21 (70)</td>
<td>19 (76)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>IgA</td>
<td>22 (73)</td>
<td>21 (84)</td>
<td></td>
</tr>
<tr>
<td>Ro 60</td>
<td>IgG</td>
<td>16 (53)</td>
<td>14 (56)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>IgM</td>
<td>7 (23)</td>
<td>6 (24)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>IgA</td>
<td>14 (47)</td>
<td>13 (52)</td>
<td></td>
</tr>
<tr>
<td>La</td>
<td>IgG</td>
<td>21 (70)</td>
<td>20 (80)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>IgM</td>
<td>20 (67)</td>
<td>19 (76)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>IgA</td>
<td>20 (67)</td>
<td>20 (80)</td>
<td></td>
</tr>
<tr>
<td>MaBP</td>
<td>IgG</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>IgM</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>IgA</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

MaBP (Maltose binding protein) is the fusion partner for the recombinant antigens.

IMMUNOBLOTTING

Affinity purified recombinant proteins were run by SDS-PAGE on homogeneous 10% gels under reducing conditions and thereafter transferred electrophoretically to 0.2 µm nitrocellulose membranes (Protran, Dassel, Germany). The membranes were washed twice with PBS-TW and incubated by nephelometry (Beckman-array, Beckman, USA).

STATISTICAL ANALYSIS

Pearson’s χ² test was used to analyse the semiquantitative data of Ro 52 kDa, Ro 60 kDa and La 48 kDa autoantibodies in relation to clinical data. A p value < 0.05 was considered significant.

Results

SEMIQUANTITATIVE DETECTION OF ANTIBODIES

Serial dilutions of the chimeric anti-NIP antibodies were used to verify the sensitivity of the immunoblotting method. The detection limits for IgA, IgG and IgM were 1, 1 and 6 ng/ml, respectively, which after multiplication with the dilution factors correspond to a sensitivity in serum of 0.25, 2.0 and 1.5 µg/ml, respectively. An example of this semiquantitative procedure is illustrated for IgA anti-NIP (fig 2) and it was used to divide the autoantibody levels into four groups according to the following ranges: for IgG < 2.0 µg/ml (−), 2.0–4.0 µg/ml (+), 4.0–8.0 µg/ml (++) and...
depletion procedure in two sera containing 9.3, 3.2 and 1.1 g/l; and 10.4, 4.3 and 1.1 g/l of IgG, IgA and IgM, respectively. The concentrations of IgG, IgA and IgM were measured a 10-fold dilution by nephelometry before and after protein G treatment. The results show that >98% of the IgG was depleted in both sera whereas IgA and IgM were not affected at all (<2%).

In the 30 SLE patients IgA autoantibodies to Ro 52 kDa, Ro 60 kDa and La 48 kDa were detected in 73%, 47% and 67% of the patients respectively (table 1). Similar but slightly higher frequencies were obtained in the 25 pSS patients for whom the corresponding figures were 84%, 52% and 80%, respectively. Figure 3 shows the representative immunoblotting results for IgA autoantibodies to Ro 52 kDa and Ro 60 kDa.

The frequency of detectable IgG and IgM autoantibodies to the three antigens was similar to those obtained for IgA in both patient groups (table 1). The only difference was a lower frequency of IgM anti-Ro 60 kDa antibodies compared with those of IgA and IgG in both SLE and pSS patients (table 1).

No IgA, IgG or IgM autoantibodies to Ro 52 kDa, Ro 60 kDa and La/SSB were detected in the 20 sera of the control group. Moreover, there were no reactions to the wild type MaBP-fusion protein in any of the sera from the patient or healthy control groups (data not shown).

The semiquantitative procedure was used to divide the results into four groups and allowed comparison of autoantibody levels of the three classes of immunoglobulins (fig 4). The median serum levels in the SLE and pSS patients were calculated and showed that IgG autoantibodies dominated in concentration followed by IgM > IgA. The same pattern was seen for both patient groups and for all three antigens (fig 4).

A comparison of the number of patients having various combinations of detectable IgA, IgG and IgM autoantibodies was illustrated in table 2. As shown most SLE patients were both IgG and IgM positive to Ro 52 kDa (63%) and La (60%). IgG was most common among patients with either IgG or IgM positivity whereas 13% (Ro 52 kDa) and 20% (La) were both IgG and IgM negative. For Ro 60 kDa the figures were the other way around and most patients were both IgG and IgM negative (43%) with only 20% being both IgG and IgM positive. The corresponding calculations for pSS patients gave very similar results (table 2).

The probability of having an IgA response in IgG/IgM positive patients was near 100% for both patient groups and towards all three antigens (table 2). A decline in this probability among patients being either IgG or IgM positive was observed mainly for patients with SLE. Finally, an exclusive IgA response was recorded in two patients with SLE who both had a weak 1+ reactivity against Ro 60 kDa.

### Epitope Recognition

A representative group of serum samples having IgA, IgG or IgM autoantibodies to...
Table 2  Number of patients with SLE and pSS having various combinations of detectable IgA, IgG and IgM autoantibodies

<table>
<thead>
<tr>
<th>IgG/IgM*</th>
<th>IgG/IgM</th>
</tr>
</thead>
<tbody>
<tr>
<td>IgG/IgM*</td>
<td>IgG/IgM</td>
</tr>
<tr>
<td>n (%)</td>
<td>n (%)</td>
</tr>
<tr>
<td>-----------</td>
<td>---------</td>
</tr>
<tr>
<td>SLE</td>
<td>+/+</td>
</tr>
<tr>
<td></td>
<td>+/-</td>
</tr>
<tr>
<td></td>
<td>+/−</td>
</tr>
<tr>
<td></td>
<td>−/−</td>
</tr>
<tr>
<td>pSS</td>
<td>+/+</td>
</tr>
<tr>
<td></td>
<td>+/−</td>
</tr>
<tr>
<td></td>
<td>−/−</td>
</tr>
<tr>
<td></td>
<td>−/−</td>
</tr>
</tbody>
</table>

*Indicates the number of patients (n) with detectable levels of IgG and/or IgM autoantibodies (that is, ≥1+ reactivity in immunoblotting). †Indicates the number of patients (n) with detectable IgA autoantibodies.

Table 3  Epitope recognition of IgG, IgM and IgA autoantibodies to different subfragments* of the Ro 52 kDa and Ro 60 kDa proteins

<table>
<thead>
<tr>
<th>Ro 52 kDa</th>
<th>Ro 60 kDa</th>
<th>La</th>
</tr>
</thead>
<tbody>
<tr>
<td>IgG† n (%)</td>
<td>IgA† n (%)</td>
<td>IgA† n (%)</td>
</tr>
<tr>
<td>52-4</td>
<td>52-5</td>
<td>52-6</td>
</tr>
<tr>
<td>n (%)</td>
<td>n (%)</td>
<td>n (%)</td>
</tr>
<tr>
<td>SLE</td>
<td>52-6</td>
<td>60-E</td>
</tr>
<tr>
<td>IgG</td>
<td>52-6</td>
<td>60-E</td>
</tr>
<tr>
<td>8</td>
<td>6 (75)</td>
<td>6</td>
</tr>
<tr>
<td>60</td>
<td>4 (50)</td>
<td>7</td>
</tr>
<tr>
<td>60-K</td>
<td>60-K</td>
<td>60-K</td>
</tr>
<tr>
<td>8</td>
<td>6 (75)</td>
<td>6</td>
</tr>
</tbody>
</table>

*The subfragments are illustrated in figure 1. †Number of patients with positive immunoblotting to full length Ro 52 kDa and Ro 60 kDa, and their subfragments, respectively.

recombinant Ro 52 kDa and Ro 60 kDa proteins were selected for epitope studies. Thus, eight sera from patients with pSS, eight sera from patients with SLE and six sera from the control group were tested against three recombinant subfragments of Ro 52 (52-4, 52-5, 52-6) and three subfragments of Ro 60 (60-E, 60-G, 60-K) (fig 1). The reactivity pattern of IgA autoantibodies was similar to those observed for IgG and IgM in both groups of patients, except for one SLE patient who had a clear IgA reactivity against the C-terminal part of Ro 60 kDa protein (table 3 and fig 3). All six control sera were negative to all subfragments.

CLINICAL CORRELATION TO SPECIFIC AUTOANTIBODIES

The semiquantitative data of IgA autoantibodies to Ro 52 kDa, Ro 60 kDa and La 48 kDa were compared with several clinical and serological features of pSS and SLE patients (table 4). Significant but weak correlations were found between sicca (defined as keratoconjunctivitis and an inflamed salivary gland) and IgA antibodies to Ro 52 kDa (p= 0.032) and La/SSB (p= 0.029). Similarly, weak correlations were obtained for IgG (p< 0.05) but not for IgM. No correlations between anti-Ro 60 kDa antibodies and any clinical parameters were noted.

Discussion

Table 4  Clinical symptoms and IgA antibody repertoire to Ro 52, Ro 60 and La antigens in patients with pSS (n=25) and SLE (n=30)

<table>
<thead>
<tr>
<th>Immunoblot reactivity</th>
<th>Patients (n)*</th>
<th>Diagnosis</th>
<th>RF</th>
<th>Dermal manifestations</th>
<th>Serositis</th>
<th>Nephritis</th>
<th>Arthritis</th>
<th>Haematological manifestations</th>
<th>CNS</th>
<th>Sccia oral</th>
<th>Sccia ocular</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ro 52+60+La</td>
<td>13</td>
<td>pSS</td>
<td>10</td>
<td>5</td>
<td>0</td>
<td>1</td>
<td>8</td>
<td>2</td>
<td>1</td>
<td>13</td>
<td>13</td>
</tr>
<tr>
<td>Ro 52+ La</td>
<td>7</td>
<td>pSS</td>
<td>5</td>
<td>3</td>
<td>0</td>
<td>2</td>
<td>2</td>
<td>3</td>
<td>0</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>Ro 52 + 60</td>
<td>0</td>
<td>pSS</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Ro 52 only</td>
<td>1</td>
<td>pSS</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Ro 60 only</td>
<td>0</td>
<td>pSS</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>La only</td>
<td>0</td>
<td>pSS</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>No reaction</td>
<td>4</td>
<td>pSS</td>
<td>3</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>4</td>
<td>2</td>
<td>0</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Ro 52+60+La</td>
<td>11</td>
<td>SLE</td>
<td>4</td>
<td>10</td>
<td>7</td>
<td>3</td>
<td>9</td>
<td>6</td>
<td>3</td>
<td>5</td>
<td>6</td>
</tr>
<tr>
<td>Ro 52+ La</td>
<td>8</td>
<td>SLE</td>
<td>3</td>
<td>7</td>
<td>6</td>
<td>1</td>
<td>3</td>
<td>5</td>
<td>2</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Ro 52 + 60</td>
<td>2</td>
<td>SLE</td>
<td>0</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Ro 52 only</td>
<td>1</td>
<td>SLE</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Ro 60 only</td>
<td>1</td>
<td>SLE</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>La only</td>
<td>2</td>
<td>SLE</td>
<td>0</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>No reaction</td>
<td>5</td>
<td>SLE</td>
<td>0</td>
<td>4</td>
<td>3</td>
<td>0</td>
<td>3</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>2</td>
</tr>
</tbody>
</table>

*Number of patients with a positive immunoblot (≥1+ reaction).

Previous studies have indicated that some patients diagnosed with SLE and SS and who are Ro/La positive by immunodiffusion or counter immunoelectrophoresis have undetectable antibody levels by ELISA and immunoblotting. 35 36 These differences may be related to a variability in epitope/antigen characteristics in various techniques. Antigens or epitopes may be lacking and/or be susceptible to immobilisation and sample treatments. Our results suggest that these technique related discrepancies cannot be explained by IgA as nearly all patients negative for IgG and IgM antibodies also were IgA negative.

Epitope studies with subfragments of Ro 52 kDa and Ro 60 kDa have previously shown that IgG antibodies react mainly with the N-terminal and middle parts of the antigen. 35 36 Our results indicate that IgA as well as IgM autoantibodies follow the same reactivity pattern suggesting common immunodominant regions for these three classes of immunoglobulins. Interestingly one SLE
patient reacted with the C-terminal part of Ro 60 kDa a specificity equally uncommon among IgG and IgM antibodies. Moreover, two SLE patients had an exclusive IgA response against Ro 60 kDa and we observed a lower frequency of IgM anti-Ro 60 kDa antibodies as compared with those of IgG and IgA in both SLE and pSS patients. The reasons for these findings are unclear but they might bear on differences in antibody affinity and/or epitope conformation. The physiological and diagnostic implications of these different specificities need further studies.

IgA is the main isotype produced locally by the mucosal tissue. Mucosal antibodies are functionally important to protect againstviruses and bacteria in both mucosal and systemic compartments. The molecular size of IgA antibodies may influence their biological effects. Polymeric IgA, which is present in plasma, is able to activate the alternative pathway of the complement system. Polymeric IgA binds stronger to cellular receptors and is therefore more effective than monomeric IgA. This suggests that polymeric IgA autoantibodies might be more effective in inducing tissue damage than monomeric IgA. However, we presently do not know the IgA subclass or polymeric forms of the observed IgA autoantibodies. IgA immunoglobulin have been found deposited in the glomeruli of SLE patients with nephritis. It would be interesting to determine if Ro 52 kDa, 60 kDa and La antigen participate in such IgA complexes.

Measurements of antigen specific autoantibodies in serum of patients with autoimmune disease by various immunoassays may give erroneous results for different reasons. Besides background caused by non-specific binding to the solid phase class specific rheumatoid factors commonly found in SLE and SS sera may either directly react with unspecified or specific IgG, or they may capture enzyme conjugates of IgG type. To minimise these drawbacks we used an efficient blocking buffer, IgG depleted serum and enzyme conjugates in the form of F(ab'), fragments. We also used chimeric antibodies to evaluate the sensitivity and improve on the comparison between immunoblotting experiments. This attempt to semiquantify the antibody concentrations demonstrated that IgG dominates the autoantibody response in both SLE and pSS with a similar median concentration in serum of 5–8 µg/ml against all tested antigens. The corresponding median concentrations for IgM (2–3 µg/ml) and IgA (0.5–1.0 µg/ml) were slightly lower. Still, the relatively high concentration of IgA antibodies suggests physiological implications.

We are unaware of any previous attempts to correlate IgA anti-Ro/SSA and anti-La/SSB autoantibodies to clinical features in patients with SsS or SLE. However, we were unable to find any major link to any particular clinical feature besides a weak correlation between sicca symptoms, and the presence of IgA anti-Ro 52 kDa and IgA anti-La, respectively.

In conclusion, we have demonstrated a high frequency of IgA anti-Ro/SSA and anti-La/SSB autoantibodies in serum of patients with pSS and SLE. Our semiquantitative immunoblotting approach suggests that IgG dominates the autoantibody response followed by IgM and IgA. The epitope specificity of the IgA autoantibodies closely followed that of IgG and IgM. The diagnostic and physiological relevance of IgA autoantibodies in SS and SLE need further evaluation.

We gratefully acknowledge Mrs Evi Melilloquist and Mrs Maggy Magnusson for outstanding technical assistance.

Funding: research support for this study was provided by the Swedish Society for Medicine; the Royal Swedish Academy of Sciences; The Swedish Foundation of Health Care Sciences and Allergy Research; Karolinska Institute; Jubilee Foundation of Disease Insurance; the Swedish Rheumatism Association; the Swedish Medical Research Council; the Swedish Foundation for Strategic Research; The Royal Swedish Academy of Sciences; the Tornspiran, Hessellman and Consult Ts C Bergh; Lundström, the Magnus Bergvall, Professor Nanna Svanström, King Gustaf V:s 80-year, Åke Wiberg, Eva and Alex Wallström and B Dahl Foundation.

Ro/SSA and La/SSB specific IgA autoantibodies in serum of patients with Sjögren's syndrome and systemic lupus erythematosus

Nader Pourmand, Marie Wahren-Herlenius, Iva Gunnarsson, Elisabet Svenungsson, Björn Löfström, Yiannakis Ioannou, David A Isenberg and Carl G M Magnusson

Ann Rheum Dis 1999 58: 623-629
doi: 10.1136/ard.58.10.623

Updated information and services can be found at:
http://ard.bmj.com/content/58/10/623

These include:

References
This article cites 46 articles, 13 of which you can access for free at:
http://ard.bmj.com/content/58/10/623#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Immunology (including allergy) (5144)
- Connective tissue disease (4253)
- Systemic lupus erythematosus (571)
- Inflammation (1251)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/